Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES)

PHASE3CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 28, 2019

Primary Completion Date

June 21, 2021

Study Completion Date

September 28, 2021

Conditions
Extrathoracic Sarcoidosis
Interventions
DRUG

Infliximab

An initial period with 2 injections with infliximab allowing the determination of the primary criteria Then an extension with infliximab with 3 supplementary perfusions

DRUG

Placebo

An initial period with 2 injections with placebo allowing the determination of the primary criteria Then an extension with infliximab with 5 supplementary perfusions

Trial Locations (10)

13000

Hopital de la Timone- service de Médecine Internne, Marseille

44000

CHU Hotel Dieu - service de Médecine Interne, Nantes

59000

Hopital Claude Huriez- service de Médecine Interne, Lille

67000

Nouvel Hopital Civil- service de Médecine Interne, Strasbourg

69000

Hopital de la Croix Rousse- service de Médecine Interne, Lyon

75013

GH la Pitié Salpêtrière. Service de Médecine interne, Paris

75018

Hopital BICHAT - Médecine Interne, Paris

Hopital Bichat- service de pneumologie, Paris

93000

Hopital Avicenne - service de pnaumologie, Bobigny

94000

Hopital Henri Mondor- service de Médecine Interne, Créteil

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03704610 - Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES) | Biotech Hunter | Biotech Hunter